logo
US health officials crack down on kratom-related products after complaints from supplement industry

US health officials crack down on kratom-related products after complaints from supplement industry

WASHINGTON (AP) — U.S. health officials are warning Americans about the risks of an opioid-like ingredient increasingly added to energy drinks, gummies and supplements sold at gas stations and convenience stores, recommending a nationwide ban.
The chemical, known as
7- hydroxymitragynine
, is a component of
kratom
, a plant native to Southeast Asia that has gained popularity in the U.S. as an
unapproved treatment
for pain, anxiety and drug dependence.
In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying them as dangerously strong, synthetic versions of the original ingredient.
The FDA action 'is not focused on natural kratom leaf products,' according to a statement Tuesday by the U.S. Department of Health and Human Services.
The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which also includes LSD and heroin.
'7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.'
The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances.
Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic.
Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with the drug. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety.
Supplement executives quickly applauded the move.
The FDA 'demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements.
An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements
Nearly a decade ago, the federal government came close to a national ban on the substance.
In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1 of illegal drugs. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress.
The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl.
Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders.
In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the
antidepressant tianeptine
.
Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats
Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats

Business Wire

time20 minutes ago

  • Business Wire

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Condition Affecting as Many as One in Seven Cats

SHAWNEE, Kan.--(BUSINESS WIRE)--PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats. Felycin®-CA1 is a specifically designed dosage formulation of sirolimus comprising an enteric coated delayed-release technology that results in a specific pharmacokinetic profile to ensure both the safety and effectiveness of Felycin®-CA1 for cats with HCM. The RAPACAT study was conducted to obtain conditional approval, while the HALT study is currently enrolling cats and being conducted to pursue the full new animal drug approval of Felycin®-CA1 for cats with HCM. 'The use of compounded rapamycin (sirolimus) or the human approved version of Rapamune® has not been approved by the FDA for the management of HCM in cats and has the potential to be very dangerous or even life-threatening if used in cats,' said Dr. Heather Davis DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services, Pegasus Laboratories, Inc. Feline HCM is extremely common, affecting 1 in 7 of all pet cats. In cats 9 years of age and older, the prevalence rises to approximately 1 in 3 and is a leading cause of mortality in adult cats. The disease is characterized by abnormal thickening and impaired function of the ventricular wall of the heart. While some cats remain asymptomatic, around half go on to develop congestive heart failure or other severe complications. Subclinical HCM refers to cases that have ventricular wall thickening but have not yet developed clinical signs. PBI-Gordon Companies, Inc. President & CEO Steve Clifford, added, 'We are very pleased to issue this update to provide both clarity and comfort for pet owners and veterinarians to ensure that cats with asymptomatic ventricular HCM are receiving the one and only FDA-conditionally approved prescription therapy for this condition.' Felycin®-CA1 is available now through licensed veterinarians nationwide and is set to fundamentally change the HCM treatment landscape – a market severely underserved. About PBI-Gordon Companies PBI-Gordon Companies has been in business in the Kansas City metro area since 1947 and is 100 percent employee-owned. It is the parent company to four subsidiaries which develop, manufacture, and market leading products for Turf and Ornamental (PBI-Gordon Corporation), Companion Animal Pharmaceuticals (Pegasus Laboratories & TriviumVet), and Companion Animal Nutritional Supplements and Grooming Supplies (PetAg). About Pegasus Laboratories Founded in 1986, Pegasus Laboratories is a pharmaceutical development and manufacturing organization focused on novel products to treat chronic conditions in cats, dogs, and horses. Pegasus provides full-service Contract Development and Manufacturing Organization (CDMO) focusing on the development and manufacturing with full turn-key technical services in an FDA-registered facility that is in compliance with current Good Manufacturing Practices (cGMPs). Pegasus also provides a full portfolio of pharmaceuticals, nutritional therapeutics and supplements, parasite control and surgical and wound care under the PRN® Pharmacal and Sē·Qual™ brands. About TriviumVet TriviumVet is an Ireland-based research and development company working with some of the leading veterinarians and therapeutic specialists around the world to address the gaps in disease management by developing innovative new therapeutic solutions for some of the most serious and underserved conditions. Focused on finding effective treatments for unmet needs in cardiology, renal health, pain management, gastroenterology, wellness testing, and age-related diseases.

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Con
Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Con

Business Wire

time20 minutes ago

  • Business Wire

Felycin®-CA1 (Sirolimus Delayed-Release Tablets) is the First and Only Drug FDA Approved for the Management of Ventricular Hypertrophy in Cats with Subclinical Hypertrophic Cardiomyopathy (HCM), A Con

SHAWNEE, Kan.--(BUSINESS WIRE)--PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats. Felycin®-CA1 is a specifically designed dosage formulation of sirolimus comprising an enteric coated delayed-release technology that results in a specific pharmacokinetic profile to ensure both the safety and effectiveness of Felycin®-CA1 for cats with HCM. The RAPACAT study was conducted to obtain conditional approval, while the HALT study is currently enrolling cats and being conducted to pursue the full new animal drug approval of Felycin®-CA1 for cats with HCM. 'The use of compounded rapamycin (sirolimus) or the human approved version of Rapamune® has not been approved by the FDA for the management of HCM in cats and has the potential to be very dangerous or even life-threatening if used in cats,' said Dr. Heather Davis DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services, Pegasus Laboratories, Inc. Feline HCM is extremely common, affecting 1 in 7 of all pet cats. In cats 9 years of age and older, the prevalence rises to approximately 1 in 3 and is a leading cause of mortality in adult cats. The disease is characterized by abnormal thickening and impaired function of the ventricular wall of the heart. While some cats remain asymptomatic, around half go on to develop congestive heart failure or other severe complications. Subclinical HCM refers to cases that have ventricular wall thickening but have not yet developed clinical signs. PBI-Gordon Companies, Inc. President & CEO Steve Clifford, added, 'We are very pleased to issue this update to provide both clarity and comfort for pet owners and veterinarians to ensure that cats with asymptomatic ventricular HCM are receiving the one and only FDA-conditionally approved prescription therapy for this condition.' Felycin®-CA1 is available now through licensed veterinarians nationwide and is set to fundamentally change the HCM treatment landscape – a market severely underserved. About PBI-Gordon Companies PBI-Gordon Companies has been in business in the Kansas City metro area since 1947 and is 100 percent employee-owned. It is the parent company to four subsidiaries which develop, manufacture, and market leading products for Turf and Ornamental (PBI-Gordon Corporation), Companion Animal Pharmaceuticals (Pegasus Laboratories & TriviumVet), and Companion Animal Nutritional Supplements and Grooming Supplies (PetAg). About Pegasus Laboratories Founded in 1986, Pegasus Laboratories is a pharmaceutical development and manufacturing organization focused on novel products to treat chronic conditions in cats, dogs, and horses. Pegasus provides full-service Contract Development and Manufacturing Organization (CDMO) focusing on the development and manufacturing with full turn-key technical services in an FDA-registered facility that is in compliance with current Good Manufacturing Practices (cGMPs). Pegasus also provides a full portfolio of pharmaceuticals, nutritional therapeutics and supplements, parasite control and surgical and wound care under the PRN® Pharmacal and Sē·Qual™ brands. About TriviumVet TriviumVet is an Ireland-based research and development company working with some of the leading veterinarians and therapeutic specialists around the world to address the gaps in disease management by developing innovative new therapeutic solutions for some of the most serious and underserved conditions. Focused on finding effective treatments for unmet needs in cardiology, renal health, pain management, gastroenterology, wellness testing, and age-related diseases.

Dozens killed while seeking aid at Gaza crossing as US envoy heads to Israel for talks
Dozens killed while seeking aid at Gaza crossing as US envoy heads to Israel for talks

Hamilton Spectator

time20 minutes ago

  • Hamilton Spectator

Dozens killed while seeking aid at Gaza crossing as US envoy heads to Israel for talks

DEIR AL-BALAH, Gaza Strip (AP) — At least 37 Palestinians were killed on Wednesday while waiting for food at a crossing in the Gaza Strip, according to a local hospital that received the casualties. The latest violence around aid distribution came as the U.S. Mideast envoy was heading to Israel for talks. Shifa Hospital in Gaza City said the dead and wounded were among crowds massed at the Zikim Crossing, the main entry point for humanitarian aid to northern Gaza. It was not immediately clear who opened fire and there was no immediate comment from the Israeli military, which controls the crossing. Israeli strikes and gunfire had earlier killed at least 46 Palestinians overnight and into Wednesday, most of them among crowds seeking food, health officials said. Israel has come under mounting international pressure in recent days as its ongoing military offensive and blockade have led to the 'worst-case scenario of famine' in the coastal territory of some 2 million Palestinians, according to the leading international authority on hunger crises. U.S. envoy Steve Witkoff, who has led the Trump administration's efforts to wind down the nearly 22-month war and release hostages taken in Hamas' Oct. 7 attack that sparked the conflict, will arrive in Israel on Thursday for talks on the situation in Gaza. A U.S. official confirmed the visit, speaking on condition of anonymity to discuss plans not yet made public. Of those killed in the earlier violence, more than 30 were seeking humanitarian aid, according to hospitals that received the bodies and treated dozens of wounded people. Another seven Palestinians, including a child, died of malnutrition-related causes , according to the Gaza Health Ministry. The Israeli military did not immediately comment on any of the strikes. It says it only targets militants and blames civilian deaths on Hamas, because the group's militants operate in densely populated areas. Strikes and gunfire at aid sites Shifa Hospital in Gaza City said that it received 12 people who were killed Tuesday night when Israeli forces opened fire toward crowds awaiting aid trucks coming from the Zikim crossing in northern Gaza. Thirteen others were killed in strikes in the urban Jabaliya refugee camp, and the northern towns of Beit Lahiya and Beit Hanoun, the hospital said. In the southern city of Khan Younis, Nasser Hospital said it received the bodies of 16 people who it says were killed Tuesday evening while waiting for aid trucks close to the newly-built Morag corridor, which the Israeli military carved out between Khan Younis and the southernmost city of Rafah. The hospital received another body of a man killed in a strike on a tent in Khan Younis, it said. The Awda hospital in the urban Nuseirat refugee camp said that it received the bodies of four Palestinians. It said they were killed Wednesday by Israeli fire close to an aid distribution site run by the Gaza Humanitarian Foundation , or GHF, in the Netzarim corridor area, south of the Wadi Gaza. Israel has eased its blockade but obstacles remain Under heavy international pressure, Israel announced a series of measures over the weekend to facilitate the entry of more international aid to Gaza, but aid workers say much more is needed. The Integrated Food Security Phase Classification, or IPC, the leading world authority on hunger crises, has stopped short of declaring famine in Gaza but said Tuesday that the situation has dramatically worsened and warned of 'widespread death' without immediate action. COGAT, the Israeli military body that facilitates the entry of aid, said over 220 trucks entered Gaza on Tuesday. That's far below the 500-600 trucks a day that U.N. agencies say are needed, and which entered during a six-week ceasefire earlier this year. The United Nations is still struggling to deliver the aid that does enter the strip, with most trucks unloaded by crowds in zones controlled by the Israeli military. The alternative aid system run by the Israeli-backed GHF has also been marred by violence. More than 1,000 Palestinians have been killed while seeking aid since May, most near sites run by GHF, according to witnesses, local health officials and the U.N. human rights office. The Israeli military says it has only fired warning shots at people who approach its forces, and GHF says its armed contractors have only used pepper spray or fired warning shots to prevent deadly crowding. International airdrops of aid have also resumed, but many of the parcels have landed in areas that Palestinians have been told to evacuate while others have plunged into the Mediterranean Sea, forcing people to swim out to retrieve drenched bags of flour. Deaths from malnutrition A total of 89 children have died of malnutrition since the war began in Gaza. The ministry said that 65 Palestinian adults have also died of malnutrition-related causes across Gaza since late June, when it started counting deaths among adults. Israel denies there is any starvation in Gaza, rejecting accounts to the contrary from witnesses, U.N. agencies and aid groups, and says the focus on hunger undermines ceasefire efforts. Hamas started the war with its attack on southern Israel on Oct. 7, 2023, in which militants killed around 1,200 people and abducted 251 others. They still hold 50 hostages, including around 20 believed to be alive. Most of the rest of the hostages were released in ceasefires or other deals. Israel's retaliatory offensive has killed more than 60,000 Palestinians, according to Gaza's Health Ministry. Its count doesn't distinguish between militants and civilians. The ministry operates under the Hamas government. The U.N. and other international organizations see it as the most reliable source of data on casualties. ___ Magdy reported from Cairo. Associated Press writer Matthew Lee in Washington contributed to this report. ___ Follow AP's war coverage at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store